Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dapagliflozin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    145 result(s) found for: Dapagliflozin. Displaying page 2 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2022-000596-40 Sponsor Protocol Number: 112930 Start Date*: 2023-01-10
    Sponsor Name:Radboudumc
    Full Title: Effect of dapaglifozin on serum magnesium in HNF1β patients with renal hypomagnesemia
    Medical condition: Renal hypomagnesemia in ADTKD-HNF1β patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001569-17 Sponsor Protocol Number: T1DM_IAH_dapa Start Date*: 2018-08-17
    Sponsor Name:Radboud university medical center
    Full Title: Effect of the SGLT-2 inhibitor dapagliflozin on impaired awareness of hypoglycemia in type 1 diabetes
    Medical condition: Type 1 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003283-31 Sponsor Protocol Number: NL67170.068.18 Start Date*: 2019-03-13
    Sponsor Name:School of Nutrition and Translational research in Metabolism (NUTRIM), Maastricht University
    Full Title: MaasFlex: A Double-Blind, Randomized, Phase IV, Mechanistic, Placebo-Controlled, Cross-Over, Single-Center Study to Evaluate the Effects of 2 Weeks Dapagliflozin Treatment on Nocturnal Substrate Ox...
    Medical condition: Study to investigate the effect of dapagliflozin treatment on nocturnal substrate oxidation in overweight and obese subjects with a disrupted glucose homeostasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001417-24 Sponsor Protocol Number: PLEIADES Start Date*: 2017-02-22
    Sponsor Name:Franciscus Gasthuis
    Full Title: POSTPRANDIAL LIPEMIA, INFLAMMATION, AND VASCULAR FUNCTION IN DIABETES MODULATED BY SGLT2 INHIBITION
    Medical condition: Diabetes Mellitus type II
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003820-58 Sponsor Protocol Number: D1690C00063 Start Date*: 2018-02-08
    Sponsor Name:AstraZeneca AB
    Full Title: A double-blind, randomized, parallel group, phase IV study to investigate the effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency and myocardial contractile work in type 2 d...
    Medical condition: type 2 diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000574-38 Sponsor Protocol Number: ESR-15-10882 Start Date*: 2016-08-31
    Sponsor Name:Medical University Vienna, Gender Medicine Unit, Div. of Endocrinology, Dep of Medicine III
    Full Title: A 24 week monocentric prospective randomized, placebo-controlled trial to evaluate Efficacy of combination of Exenatide and Dapagliflozin compared to Dapagliflozin and Placebo and its effects on ...
    Medical condition: Efficacy of combination of Exenatide and Dapagliflozin compared to Dapagliflozin and Placebo and its effects on hepatic, myocardial and pancreatic fat distribution in patients with type 2 diabete...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005525-13 Sponsor Protocol Number: MK-0431-838 Start Date*: 2015-09-30
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared with the Addition of Dapagli...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000019275 10012594 Diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) FI (Completed) IE (Completed) EE (Completed) HU (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000157-37 Sponsor Protocol Number: IIS-002-2013NL-Heerspink Start Date*: 2014-05-06
    Sponsor Name:University Medical Center Groningen
    Full Title: A study to assess the anti-albuminuric effects and variability in response to dapagliflozin in subjects with type 2 diabetes
    Medical condition: Patients with type 2 diabetes and albuminuria between 100 and 3500 mg/g.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000481-14 Sponsor Protocol Number: APHP210166 Start Date*: 2021-12-20
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: Cardiometabolic effects of dapagliflozin in heart failure with reduced ejection fraction: an exploratory study.
    Medical condition: Heart failure with reduced ejection fraction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005842-41 Sponsor Protocol Number: 20-687 Start Date*: 2021-01-22
    Sponsor Name:KRKA, d.d., Novo mesto
    Full Title: COMPARATIVE, RANDOMISED, SINGLE-DOSE, CROSSOVER, 3-WAY BIOAVAILABILITY STUDY OF DAPAGLIFLOZIN 10 mg FORMULATIONS IN HEALTHY VOLUNTEERS UNDER FED CONDITIONS
    Medical condition: Healthy voluneers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003552-31 Sponsor Protocol Number: ESR-14-10179 Start Date*: 2014-11-28
    Sponsor Name:Kinderkrankenhaus AUF DER BULT
    Full Title: A Randomized, Double-Blind, Placebo-controlled, Single-center Phase 1 Pilot Study to Explore the Safety and Pharmacokinetics of a Single-Dose of DAPAglifozin as Add-on to Intravenous Insulin-Infusi...
    Medical condition: Type 1 Diabetes mellitus
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003503-29 Sponsor Protocol Number: D5553C00003 Start Date*: 2014-12-16
    Sponsor Name:AstraZeneca AB
    Full Title: A 28-week, Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study with a 24-week Extension Phase Followed by a 52-week Extension Phase to Evaluate the Efficacy and Safety of Simult...
    Medical condition: Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10012602 Diabetes mellitus (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-001334-21 Sponsor Protocol Number: 350A Start Date*: 2015-08-31
    Sponsor Name:Lund University
    Full Title: Study of the Effect of Vildagliptin versus Dapagliflozin on Glucagon Response to Mixed Meal in Metformin-treated Subjects with Type 2 Diabetes
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004101-32 Sponsor Protocol Number: D4325C00001 Start Date*: 2021-04-06
    Sponsor Name:AstraZeneca
    Full Title: A Phase 2b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients w...
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) BG (Completed) DK (Completed) IT (Completed) ES (Restarted) SK (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2017-001090-16 Sponsor Protocol Number: 2017003001 Start Date*: 2017-09-22
    Sponsor Name:University Medical Center Groningen
    Full Title: A Study to Assess the Renoprotective Effects of the SGLT2 Inhibitor Dapagliflozin in Non-Diabetic Patients With Proteinuria: a Randomized Double Blind 6-Weeks Cross-Over Trial
    Medical condition: Chronic kidney disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005713-40 Sponsor Protocol Number: 69HCL20_1135 Start Date*: 2021-08-02
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure patients on heart transplant waiting list: a multicenter, double-blind, randomized clinical trial.
    Medical condition: for advanced Heart Failure patients on heart transplant waiting list
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-002961-79 Sponsor Protocol Number: D1690C00049 Start Date*: 2017-05-23
    Sponsor Name:AstraZeneca AB
    Full Title: DAPASALT: An Open Label, Phase IV, Mechanistic, Three-Arm Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin treatment in Type 2 Diabetes Mellitus Patients with Either Preserved or Im...
    Medical condition: Type 2 Diabetes Mellitus patients with impaired renal function. Type 2 Diabetes Mellitus patients with normal renal function. Non-diabetic patients with impaired renal function.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003788-39 Sponsor Protocol Number: ESR-14-10231 Start Date*: 2014-12-17
    Sponsor Name:Profil Mainz GmbH & Co KG
    Full Title: Effect of Saxagliptin in Addition to Dapagliflozin and Metformin on Insulin Resistance, Islet Cell Dysfunction, and Metabolic Control in Subjects with Type 2 Diabetes Mellitus on Previous Metformin...
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003126-23 Sponsor Protocol Number: D6402C00001 Start Date*: 2021-02-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2b, Randomised, Double-Blind, Active-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients with Heart Fail...
    Medical condition: Heart Failure and Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) LT (Completed) HU (Completed) DK (Completed) SE (Completed) CZ (Completed) SK (Completed) BG (Completed) PL (Completed) DE (Completed) IT (Completed) ES (Restarted)
    Trial results: View results
    EudraCT Number: 2015-003873-13 Sponsor Protocol Number: ESR-14-10613/D1690L00044 Start Date*: 2016-02-25
    Sponsor Name:Institute for the Study, Research and Education in Diabetes Mellitus and Metabolic Disorders
    Full Title: Evaluation of the tubular effects of dapagliflozin using 1HNMR spectroscopy.
    Medical condition: Diabetes mellitus type 2.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:56:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA